BMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Eli Lilly (LLY) PT Cut to $92 at Leerink PartnersNovember 23, 2016 2:57 PM Streetinsider.com's Hot Lunchtime Reads 11/23: (JUNO) (AMZN) (AXON) (LLY)November 23, 2016 12:30 PM Eli Lilly & Co. (LLY) 30-day call option implied volatility is at 66, compared to a one month ago level of 24.November 23, 2016 11:47 AM Lilly's (LLY) Solanezumab Phase 3 Miss is Credit-Negative Event - Moody'sNovember 23, 2016 11:41 AM Options with increasing volume: BYD LLY VRX CELG URBN CTRP HPQ DE GME MUNovember 23, 2016 9:51 AM Neurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's diseaseNovember 23, 2016 9:50 AM Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)November 23, 2016 9:24 AM Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - LeerinkNovember 23, 2016 7:57 AM Axovant Sciences (AXON) Sinks 17% on Eli Lilly Sola FailureNovember 23, 2016 7:50 AM Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - LeerinkNovember 23, 2016 7:48 AM Dow, S&P 500 set record high closes ahead of holidayNovember 23, 2016 7:33 AM Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBCNovember 23, 2016 7:22 AM Eli Lilly & Co. (LLY) Sinks 11% on Solanezumab FailureNovember 23, 2016 6:54 AM Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab FailureNovember 23, 2016 6:52 AM Eli Lilly & Co. (LLY) volatility elevated into Alzheimer's data November 23, 2016 6:51 AM Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary EndpointNovember 23, 2016 6:45 AM